Gilead Sciences Inc at Piper Sandler Healthcare Conference Transcript
All right. Good morning. Thank you, everyone, for joining us for our next company presentation. My name is Do Kim. I am one of the senior biotech analysts here at Piper. And we have with us Gilead. And it's my pleasure to welcome CMO, Merdad Parsey. Merdad, thank you for being here.
My pleasure. Thanks for having me.
Questions & Answers
So Gilead has always had a tremendous R&D effort in maintaining its leadership in HIV and viral diseases. But you're always pursuing expansion in other therapeutic areas like oncology and inflammatory diseases. Just so starting out with your oncology efforts. Normally, Trodelvy would be the initial topic, but you put out a press release on your TIGIT interim fourth look, ARC-7 and were expected detailed data in -- toward the second half of December.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
